Annexon ANNX 深 沪
已收盘 08-01 16:00:00 美东时间
2.45
+0.050
+2.08%
华盛通- 最 高2.47
- 今 开2.35
- 成交量 87.20万股
- 最 低 2.2901
- 昨 收 2.40
- 总市值 2.70亿
- 52周最高 7.85
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.285
- 委 比 69.06%
- 总股本 1.10亿
- 历史最高 38.01
- 量 比 1.01
- 振 幅 7.50%
- 历史最低 1.285
- 每 手 1
- 风险率 1.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
Biopharmaceutical company Annexon, Inc. has successfully completed enrollment for its Phase 3 ARCHER II trial of vonaprument for dry age-related macular degeneration (AMD) with geographic atrophy (GA), surpassing the target of 630 participants. Vonaprument, a novel antibody fragment targeting C1q to protect vision, is set to report pivotal data in the second half of 2026. The trial aims to confirm visual acuity protection and structural benefits ...
07-24 11:00
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
Dr. Lloyd Clark, a retina specialist with 25 years of experience, has been appointed as senior vice president of ophthalmology strategy and innovation at Annexon. ANX007, a novel therapy, has shown significant vision preservation in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). The Phase 3 ARCHER II trial, evaluating ANX007, expects to complete enrollment in Q3 2025, with topline data anticipate...
06-18 20:05
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
ANNEXON, Inc. (Nasdaq: ANNX), a biopharmaceutical company developing novel therapies for complement-mediated neuroinflammatory diseases, announced that CEO Douglas Love will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 8:10 a.m. EST. A live webcast and replay will be available on the company's website. Annexon focuses on targeting C1q to stop neuroinflammation in diseases affecting the body, brain, and eye, addressing ...
05-29 20:05
Annexon Presents Data Highlighting Outcomes With Tanruprubart At 2025 Peripheral Nerve Society Annual Meeting
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient
05-20 04:06
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Needham Maintains Buy on Annexon, Lowers Price Target to $11
Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and lowers the price target from $16 to $11.
05-13 18:36
Annexon Biosciences Reports Increased Q1 2025 Losses
Annexon Biosciences, Inc. ( ($ANNX) ) has released its Q1 earnings. Here is a b...
05-13 12:20
Annexon Q1 EPS $(0.37) Misses $(0.29) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 76.19 percent decrease over losses of $(0.21) per share from the
05-12 20:02
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
Dexcom G7 15-Day CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features.
04-11 01:28
